Bangalore-based Biocon has reached the clinical stage with its two generic insulin and biosimular drugs that may be game-changers soon in the treatment of diabetes.
The drugs, developed in partnership with Mylan, the Two molecules Pegfilgrastim (PEG-G-CSF), which has successfully cleared the first two stages and the third global Phase 3 clinical trials will commence soon for the PEG-G-CSF trial. The other drug Adalimumab is underway its initial clinicl test, said the company.
Its generic Insulin Glargine is underway since 2014, entering its second phase for type 2 diabetes to be held before July thi year, said the company.
Biocon CEO Dr Arun Chandavarkar said, "We can build a strong global presence in generic Insulin analogs and biosimilars like monoclonal antibodies and recombinant proteins to address the need for affordable access to these biologics."
In addition, the company is now focusing on generic insulin analog products and a high-value portfolio of biosimilars for oncology and autoimmune indications.
Currently, Biocon conducting clinical trials for five molecules in Phase 3 for — Glargine, Pegfilgrastim, Adalimumab, Bevacizumab and Trastuzumab.